- Home
- EXR vs ONC Comparison
EXR vs ONC Comparison
Compare EXR & ONC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EXR | ONC |
|---|---|---|
| Founded | 1977 | 2010 |
| Country | United States | Switzerland |
| Employees | N/A | 12000 |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.3B | 31.4B |
| IPO Year | 2004 | N/A |
Fundamental Metrics
Financial Performance| Metric | EXR | ONC |
|---|---|---|
| Price | $145.23 | $280.64 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 15 | 10 |
| Target Price | $144.80 | ★ $385.10 |
| AVG Volume (30 Days) | ★ 855.4K | 228.0K |
| Earning Date | 04-28-2026 | 05-06-2026 |
| Dividend Yield | ★ 4.61% | N/A |
| EPS Growth | ★ 13.90 | N/A |
| EPS | ★ 1.14 | N/A |
| Revenue | ★ $3,377,542,000.00 | N/A |
| Revenue This Year | N/A | $723.76 |
| Revenue Next Year | $3.63 | $15.04 |
| P/E Ratio | ★ $125.47 | $614.06 |
| Revenue Growth | ★ 3.70 | N/A |
| 52 Week Low | $125.71 | $239.25 |
| 52 Week High | $155.19 | $385.22 |
Technical Indicators
Market Signals| Indicator | EXR | ONC |
|---|---|---|
| Relative Strength Index (RSI) | 55.89 | 37.47 |
| Support Level | $136.53 | $271.47 |
| Resistance Level | $145.69 | $323.73 |
| Average True Range (ATR) | 3.28 | 7.36 |
| MACD | 0.01 | -2.82 |
| Stochastic Oscillator | 78.13 | 21.55 |
Price Performance
Historical ComparisonAbout EXR Extra Space Storage Inc
Extra Space Storage is a fully integrated real estate investment trust that owns, operates, and manages more than 4,200 self-storage properties in 43 states, with over 330 million net rentable square feet of storage space. Of these properties, approximately one half is wholly owned, while some facilities are owned through joint ventures and others are owned by third parties and managed by Extra Space Storage in exchange for a management fee.
About ONC BeiGene Ltd. American Depositary Shares
BeOne Medicines Ltd is a holding company. Through its subsidiaries, it operates as an oncology-focused biopharmaceutical company engaged in the discovery and development of treatments for cancer. Its portfolio includes BRUKINSA (a Bruton's tyrosine kinase (BTK) inhibitor), sonrotoclax (a B-cell lymphoma 2 (BCL2) inhibitor, and a BTK chimeric degradation activation compound (BTK-CDAC). The company develops and commercializes wholly owned therapeutic assets targeting multiple mechanisms of action in oncology. The company operates in one segment: pharmaceutical products. It generates the majority of its revenue from the sale of its biopharmaceutical products.